



Figure S1. A. The LumiCycle In Vivo System, single unit. B. Top, front, and side views of the cage showing the position of the PMTs above the cage. The photomultiplier tubes are located above the cage, 12.7 cm apart (center to center). Each is 6.35 cm from the center of the cage along the long axis of the cage. The PMT windows are 24 x 8 mm, oriented with the longer axis perpendicular to the longer axis of the cage. Shown in the schematic here is the PMT effective area, 20 x 4 mm.



Figure S2. Raw data for cases shown in Figure 2. For each animal, IVM82 and IVM93, the incoming counts/s detected by each of the two photomultiplier tubes (PMTs) is plotted over 7 days of recording. We then sum the counts collected each second from PMT1 and PMT2 for the final raw data files, plotted in C and F. In the case of IVM82, we also collected locomotor activity from a motion sensor; this is shown as counts/min in brown below bioluminescence (black) in C. Such data was not available for IVM93 due to software malfunction. In G and H we show on a shorter time base how the signal switched between PMT1 and PMT2, presumably as the animal moved around in the cage.



Figure S3. Drawing to demonstrate the extent of the shave administered prior to experiments in mice with black fur. The mouse was shaved in a band that extended from dorsal to ventral surface.



















Figure S5. All drinking dose response data. Individual animals are identified by the "IVMxx" number. Final data for IVM 89 (D) was lost due to equipment failure.

Figure S5





Figure S6. A) Drinking rate results for CycLuc1 vs D-luciferin comparison data. Drinking rate per day for each treatment was calculated by dividing the total volume of substrate consumed by the number of days. B) Bioluminescence records for all animals (Left - 0.1 mM D-luciferin treatment 1, center - 0.1 mM CycLuc1 treatment, right - 0.1 mM D-luciferin treatment 2). Individual animals are identified by the "IVMxx" number.



Figure S7. Evaluation of ip D-luciferin and CycLuc1 after incubation at 4 °C or 37 °C. LC/MS and in vivo bioluminescence imaging after incubation in aqueous buffer at the specified temperature for 0, 7, or 14 days in FVB/NJ mice previously receiving iv injection of AAV9-CMV-WTluc2 as previously described (Mofford et al. 2015). Shown are results from the 4 male mice tested; results were replicated with 4 female mice (not shown).



Figure S8. IVIS imaging to assess the source of bioluminescence in *Per2^{LucSV/+}* mice. Images show paired dorsal (A-D) and ventral (E-H) images from a representative male mouse from each treatment group. Mice were imaged after drinking 0.1 mM D-luciferin (A,E), 2 mM D-luciferin (B,F) or CycLuc1 (0.1 mM; C,G), or after injection of 0.1mL D-luciferin (10mM; D,H). All images are adjusted to the bioluminescence scale bar shown at right. Results shown are representative of each group (n=6-10 per group).



Figure S9. Images show a representative result
from imaging experiments that included
dissections. Photographs of the dorsal (A) and
ventral (C) views are paired with bioluminescence
images in B and D. Following dissection, the
photograph (E) and IVIS image (F) show the
majority of signal arising from the kidney.
Images adjusted to the bioluminescence scale bars
shown at right.